BioCentury | Feb 23, 2021
Product Development

FDA’s Marks says time is now to start trials for vaccines against new COVID-19 variants as agency issues guidance

FDA is outlining a streamlined clinical development path for COVID-19 vaccines against emerging variants based on clinical immunogenicity studies, and it’s time for manufacturers to start those trials,...
BioCentury | Feb 19, 2021
Product Development

Korea Spotlight: Eutilex readying first U.S. trial as cancer company aims for global stage

Eutilex hopes data from an upcoming Phase I trial of its anti-4-1BB antibody will help land the South Korean biotech a global licensing partner for the compound, VP and Head of Open Innovation and Global Strategy...
BioCentury | Feb 12, 2021
Product Development

How COVID-19 drug developers can stay ahead of viral variants

...binding, they’re still helping.”Adagio has extended the epitope...
BioCentury | Feb 12, 2021
Product Development

Tau vaccine moving toward late-stage trials for Alzheimer’s

AC Immune believes it has hit on a breakthrough in vaccine technology with its Alzheimer’s candidate ACI-35. The rest of the world will have to wait to evaluate the claim, as the company and partner...
BioCentury | Feb 11, 2021
Emerging Company Profile

BigHat: AI for antibody optimization beyond target engagement

BigHat, which raised $19 million in an A round led by Andreessen Horowitz on Wednesday, is marrying lab assays with machine learning to optimize antibodies for properties beyond target engagement.  The San Carlos, Calif.-based company’s three...
BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

...to T cells, making UB-612 also a member of the third vaccine category: T cell epitope...
...may not prevent a T cell attack. At least eight vaccine programs fall in the T cell epitope...
...Oncology Inc. (NASDAQ:GRTS). The draw was the promise of the biotech’s antigen delivery and T cell epitope...
BioCentury | Feb 3, 2021
Deals

Imcyse moves closer to next financing round with Pfizer RA deal

A new partnership with Pfizer for its RA program gets Imcyse another step closer to raising its next round of financing that would support clinical trials of its pipeline through at least 2023. On Wednesday...
BioCentury | Jan 28, 2021
Product Development

Vulnerability of COVID-19 mAbs to emerging variants: Data Byte

Data on the vulnerability of mAbs to emerging SARS-CoV-2 variants supports the hypothesis that antibodies that bind epitopes conserved across coronavirus species will be most resilient to mutations. Recent...
BioCentury | Jan 26, 2021
Product Development

Moderna’s two-pronged approach to combating emerging SARS-CoV-2 variants

Moderna is taking a two-pronged approach to addressing potentially weakened vaccine protection against SARS-CoV-2 variants by evaluating an additional booster shot of its current vaccine — a solution...
BioCentury | Jan 22, 2021
Product Development

Slaoui on Warp Speed’s successes, limitations and lessons

Having helped create the fastest vaccine development programs in history, Moncef Slaoui has stepped down as scientific adviser and co-leader of Operation Warp Speed, the U.S. government’s initiative to develop, manufacture and distribute countermeasures to COVID-19. Slaoui and...
Items per page:
1 - 10 of 1260
BioCentury | Feb 23, 2021
Product Development

FDA’s Marks says time is now to start trials for vaccines against new COVID-19 variants as agency issues guidance

FDA is outlining a streamlined clinical development path for COVID-19 vaccines against emerging variants based on clinical immunogenicity studies, and it’s time for manufacturers to start those trials,...
BioCentury | Feb 19, 2021
Product Development

Korea Spotlight: Eutilex readying first U.S. trial as cancer company aims for global stage

Eutilex hopes data from an upcoming Phase I trial of its anti-4-1BB antibody will help land the South Korean biotech a global licensing partner for the compound, VP and Head of Open Innovation and Global Strategy...
BioCentury | Feb 12, 2021
Product Development

How COVID-19 drug developers can stay ahead of viral variants

...binding, they’re still helping.”Adagio has extended the epitope...
BioCentury | Feb 12, 2021
Product Development

Tau vaccine moving toward late-stage trials for Alzheimer’s

AC Immune believes it has hit on a breakthrough in vaccine technology with its Alzheimer’s candidate ACI-35. The rest of the world will have to wait to evaluate the claim, as the company and partner...
BioCentury | Feb 11, 2021
Emerging Company Profile

BigHat: AI for antibody optimization beyond target engagement

BigHat, which raised $19 million in an A round led by Andreessen Horowitz on Wednesday, is marrying lab assays with machine learning to optimize antibodies for properties beyond target engagement.  The San Carlos, Calif.-based company’s three...
BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

...to T cells, making UB-612 also a member of the third vaccine category: T cell epitope...
...may not prevent a T cell attack. At least eight vaccine programs fall in the T cell epitope...
...Oncology Inc. (NASDAQ:GRTS). The draw was the promise of the biotech’s antigen delivery and T cell epitope...
BioCentury | Feb 3, 2021
Deals

Imcyse moves closer to next financing round with Pfizer RA deal

A new partnership with Pfizer for its RA program gets Imcyse another step closer to raising its next round of financing that would support clinical trials of its pipeline through at least 2023. On Wednesday...
BioCentury | Jan 28, 2021
Product Development

Vulnerability of COVID-19 mAbs to emerging variants: Data Byte

Data on the vulnerability of mAbs to emerging SARS-CoV-2 variants supports the hypothesis that antibodies that bind epitopes conserved across coronavirus species will be most resilient to mutations. Recent...
BioCentury | Jan 26, 2021
Product Development

Moderna’s two-pronged approach to combating emerging SARS-CoV-2 variants

Moderna is taking a two-pronged approach to addressing potentially weakened vaccine protection against SARS-CoV-2 variants by evaluating an additional booster shot of its current vaccine — a solution...
BioCentury | Jan 22, 2021
Product Development

Slaoui on Warp Speed’s successes, limitations and lessons

Having helped create the fastest vaccine development programs in history, Moncef Slaoui has stepped down as scientific adviser and co-leader of Operation Warp Speed, the U.S. government’s initiative to develop, manufacture and distribute countermeasures to COVID-19. Slaoui and...
Items per page:
1 - 10 of 1260